GSK plc (GS71)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 22.84 |
|---|---|
| 52-week range | 18.43 – 26.14 |
| Return, 1 month / 3 months | +2.8% / +2.8% |
| Return, 1 year / 3 years | +24.0% / +53.8% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 24.5% |
| Worst drawdown (1 year) | -19.0% |
| Average daily value traded | 0.78M EUR |
| Dividend yield | 4.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
GSK plc is a pharmaceutical company based in the United Kingdom that researches, develops and makes prescription medicines and vaccines. Its products address respiratory conditions, infections, HIV and other diseases, and it supplies healthcare providers, hospitals and governments around the world. The company also produces consumer healthcare brands for everyday ailments. GSK operates research and manufacturing sites internationally and serves patients through partnerships with health systems and medical professionals.
GSK plc trades under the code GS71 on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
GSK plc (GS71) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 22.84 on 22 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 120 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 24.0% and over the last three months it rose 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.1% | ||
| From 52-week high | -12.1% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.8% | ||
| 6-month return | -2.5% | ||
| 12-month return, skipping the last month | 20.6% | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.0% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.78M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 82 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 4.2% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.2% |
|---|---|
| 1 month | +2.8% |
| 3 months | +2.8% |
| 6 months | −2.5% |
| 1 year | +24.0% |
| 3 years | +53.8% |
| 5 years | +63.1% |
Signals
| 50-day / 200-day average | 21.63 / 22.36 |
|---|---|
| Golden / death cross (60 days) | Death, 30 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.46 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Aug 2026 | GBP 0.2015 |
| 14 May 2026 | GBP 0.2015 |
| 19 Feb 2026 | GBP 0.2134 |
| 13 Nov 2025 | GBP 0.1897 |
| 14 Aug 2025 | GBP 0.1897 |
| 15 May 2025 | GBP 0.1897 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.